Soleus Capital Special Opportunities Fund, L.P. 13D and 13G filings for ESSA Pharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-11 4:00 pm Sale |
2024-12-31 | 13G | ESSA Pharma Inc. EPIX |
Soleus Capital Special Opportunities Fund, L.P. | 2,262,026 5.100% |
-2,065,596 (-47.73%) |
Filing |
| 2024-01-23 4:09 pm Purchase |
2023-12-31 | 13G | ESSA Pharma Inc. EPIX |
Soleus Capital Special Opportunities Fund, L.P. | 4,327,622 9.800% |
458,230 (+11.84%) |
Filing |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | ESSA Pharma Inc. EPIX |
Soleus Capital Special Opportunities Fund, L.P. | 3,869,392 8.800% |
3,869,392 (New Position) |
Filing |